People Groups Blogs News Search: All News | knowmoremedia.com Tags | Domains | Searches | Statistics | Options | Advanced Search

knowmoremedia.com » Tags » Cancer Drugs

Related tags: allergy, cancer, drug marketing, drug regulations and approval, from the blogosphere, lung cancer, manufacturers and mergers, nhl, patents and clinical trials, research and development

1. Interesting Finds: Pharma-related Posts 9 PharmaGazette - Jul 10, 2007 Check out the following great posts from the blogosphere that I think would interest pharma business readers as well: Centrally Active ACE inhibitors May Help Reduce Risk of Cognitive Decline in Older Adults … Also tagged: cancer, allergy, aspirin, tamiflu, from the blogosphere, influenza drugs, cardiovascular drugs

2. CTI’s Pixantrone Received USFDA Fast Track Status for Relapsed Indolent NHL PharmaGazette - Jul 10, 2007 The USFDA has awarded a Fast Track Designation to Cell Therapeutics, Inc. (CTI) (Nasdaq: CTICD)’s pixantrone for relapsed indolent non-Hodgkin's lymphoma (NHL). Pixantrone is a novel anthracenedione, being … Also tagged: cancer, cti, nhl, drug regulations and approval, cell therapeutics, non hodgkin s lymphoma nhl, pixantrone

3. USFDA Awarded Orphan Drug Grant to Expression Genetics, Inc. for Clinical Development of EGEN-001 for Ovarian Cancer Treatment PharmaGazette - Jul 10, 2007 The USFDA has awarded a three-year grant of $1,050,000 to Expression Genetics, Inc. in order to assist in the clinical development of EGEN-001, the company's lead oncology product. In 2005, EGEN-001 has been given … Also tagged: cancer, ovarian cancer, research and development, patents and clinical trials, expression genetics

4. Interesting Finds: Pharma-related Posts 9 [PharmaGazette] Know More Media - Health Care / Pharmaceutical / Fitness - May 10, 2007 Check out the following great posts from the blogosphere that I think would interest pharma business readers as well: Centrally Active ACE inhibitors May Help Reduce Risk of Cognitive Decline in Older Adults … Also tagged: cancer, allergy, aspirin, tamiflu, from the blogosphere, influenza drugs, cardiovascular drugs

5. CTI’s Pixantrone Received USFDA Fast Track Status for Relapsed Indolent NHL [PharmaGazette] Know More Media - Health Care / Pharmaceutical / Fitness - May 8, 2007 The USFDA has awarded a Fast Track Designation to Cell Therapeutics, Inc. (CTI) (Nasdaq: CTICD)’s pixantrone for relapsed indolent non-Hodgkin's lymphoma (NHL). Pixantrone is a novel anthracenedione, being … Also tagged: cancer, cti, nhl, drug regulations and approval, cell therapeutics, non hodgkin s lymphoma nhl

6. USFDA Awarded Orphan Drug Grant to Expression Genetics, Inc. for Clinical Development of EGEN-001 for Ovarian Cancer Treatment [PharmaGazette] Know More Media - Health Care / Pharmaceutical / Fitness - May 5, 2007 The USFDA has awarded a three-year grant of $1,050,000 to Expression Genetics, Inc. in order to assist in the clinical development of EGEN-001, the company's lead oncology product. In 2005, EGEN-001 has been given … Also tagged: cancer, ovarian cancer, research and development, patents and clinical trials

7. ADVENTRX’s ANX-514 (Docetaxel Emulsion) Demonstrated Positive Data from Preclinical Pharmacokinetic Testing [PharmaGazette] Know More Media - Health Care / Pharmaceutical / Fitness - Apr 27, 2007 Preclinical pharmacokinetic testing of ANX-514 (docetaxel emulsion) in a well recognized animal model, yielded positive data as recently announced by ADVENTRX Pharmaceuticals, Inc. (Amex: ANX). Results of the study … Also tagged: cancer, generic drugs, patents and clinical trials

8. USFDA Gave Go Signal to Exelixis’ Clinical Trial of XL999 in Non-Small Cell Lung Cancer (NSCLC) Patients [PharmaGazette] Know More Media - Health Care / Pharmaceutical / Fitness - Apr 26, 2007 The USFDA has granted Exelixis, Inc. (Nasdaq: EXEL) the go signal to initiate its clinical trial (following approved review of the protocol) of XL999 in patients with non-small cell lung cancer (NSCLC). Developed by … Also tagged: cancer, lung cancer, patents and clinical trials, drug regulations and approval, nsclc, exelixis

9. USFDA NDA for Xcytrin® Injection for Lung Cancer Brain Metastases Treatment, Submitted by Pharmacyclics [PharmaGazette] Know More Media - Health Care / Pharmaceutical / Fitness - Apr 25, 2007 Pharmacyclics, Inc. (Nasdaq: PCYC) has recently filed a New Drug Application (NDA) to the USFDA for its Xcytrin® (motexafin gadolinium) Injection, seeking approval to market the drug for the treatment of non-small cell … Also tagged: cancer, lung cancer, nda, drug regulations and approval, nsclc

10. Allos Therapeutics’ PDX (pralatrexate), Granted EMEA Orphan Drug Designation [PharmaGazette] Know More Media - Health Care / Pharmaceutical / Fitness - Apr 20, 2007 Allos Therapeutics, Inc. (Nasdaq: ALTH)’s novel antifolate PDX (pralatrexate) for the treatment of patients with peripheral T-cell lymphoma (PTCL) has been granted Orphan Drug Designation by the European Medicines … Also tagged: cancer, nhl, drug regulations and approval, emea

1  2  3  4

About Speeple | Terms of Service | Privacy Policy | Copyright ©2007 Speeple™